New orphan drug designation for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease
Musculoskeletal disorders are injuries or pain in the human musculoskeletal system, including the joints, ligaments, muscles, nerves, tendons, and structures that support limbs, neck and back.
A recent announcement by Addex Therapeutics (Geneva, Switzerland) has highlighted the designation of dipraglurant by the US FDA as an orphan drug for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID). The development signals a key sign of support for the use of the drug in this rare disease. Dipraglurant was developed as a small molecule inhibitor of the metabotropic glutamate receptor 5 (mGluR5), with the potential for use in combination with levodopa or dopamine agonists, or as a standalone treatment for Parkinson's disease levodopa-induced dyskinesia, other motor and non-motor symptoms of Parkinson's disease and other movement disorders....
